Multiple sclerosis is a neurological disorder categorized by inflammatory processes with a
high prevalence worldwide. It affects both motor and sensory pathways and is also …

Multiple sclerosis (MS) is the most common non-traumatic cause of disability in young
people, with vision loss in the disease representing the second largest contributor to …

This study will provide a thorough review of systemic (and select intravitreal) medications,
along with illicit drugs that are capable of causing various patterns of retinal toxicity. The …

Objective To investigate the clinical features, treatment, and prognosis of fingolimod-
associated macular edema (FAME) and to provide a reference for its rational management …

This paper aims to observe and analyze the safety and clinical efficacy of Fingolimod
combined with alteplase intravenous thrombolysis in the treatment of acute ischemic stroke …

Introduction: The authors present a case of a male with Multiple Sclerosis (MS) who
developed unilateral Fingolimod-Associated Macular Edema (FAME) 10 years after initiating …

Purpose Fingolimod is the first oral drug approved for treatment of relapsing–remitting
multiple sclerosis (RR-MS), and it has potential macular side effects. Despite the qualitative …

Aim To determine changes in retinal microcirculation, caused by fingolimod (FTY720) use,
via swept-source optical coherence tomography angiography (SS-OCTA) in relapsing …

Siponimod is a sphingosine-1-phosphate receptor modulator used as disease-modifying
therapy for relapsing-remitting multiple sclerosis similar to Fingolimod which has been …

Postoperative cystoid macular oedema (CMO) is a recognised complication of cataract
surgery, occurring in around 1.5% of cases. It is generally managed with topical steroids or …